Squamous cell carcinoma
Conditions
Interventions
Experimental Group:The medication plan is 50mg, taken three times a day before meals.
Sponsors
South China Hospital of Shenzhen University
Eligibility
Sex/Gender
All
Age
No minimum to 75 Years
Inclusion criteria
Inclusion criteria: All enrolled subjects must meet all of the following criteria in order to be included in this study: 1. Diagnosed with unresectable locally advanced or advanced squamous cell carcinoma; 2. Age not exceeding 75 years old; 3.ECOG score 0-1 points; 4. Previously used a three cycle chemotherapy regimen, evaluated as SD, and it cannot be ruled out that ADC and immune checkpoint inhibitors have been used in combination; 5. After communication, I am willing to participate in this trial, promise to take the medication according to the doctor's advice, and can follow up and communicate on time.
Exclusion criteria
Exclusion criteria: Any candidate subject who meets any of the following criteria will not be enrolled in this study: 1.Any of the following circumstances: people with immune deficiency or impairment (such as AIDS patients), who are using immunosuppressive drugs or radiotherapy; Patients with fever and acute infectious diseases, including active tuberculosis, or those receiving anti tuberculosis treatment; Accompanied by severe chronic cardiovascular and cerebrovascular diseases or chronic kidney disease; 2. Merge with other tumors; 3.Known to have low immune function, acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 4.Suffering from serious cardiovascular and cerebrovascular diseases, such as myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accidents or transient ischemic attacks, or pulmonary embolism; 5.There are obvious dysfunction of major internal organs, such as creatinine>2 times the upper limit of the normal range, AST, ALT, total bilirubin>2 times the upper limit of the normal range, etc; 6.Subjects with fever and body temperature exceeding 38 ?, as well as active infections such as acute pneumonia, active tuberculosis, and severe urinary tract infections that may affect clinical trials; 7.Patients with diabetes who need to take sulfonylurea drugs and insulin for a long time; 8.Individuals who are allergic to the drug or its components; 9.Researchers believe that there may be any situation that increases the risk to participants or interferes with the execution of clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactLi Yuqing
South China Hospital of Shenzhen University
Outcome results
None listed